Company intelligence / Profile preview

DENOS

Ownership: Private
Development stage: Commercial

Overview

DENOS provides access to advanced healthcare technologies and develops digital platforms to enable personalized medicine. Its affiliate Zionexa specializes in innovative biomarkers for diagnosis and targeted therapies. The group focuses on improving patient pathways through technology integration, international collaboration, and ethical medical practice[1][2].

Modalities: BiomarkerDigital health solution
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

fluoroestradiol F-18

Commercial

Indications: Metastatic breast cancer

Partnerships

Malakoff HumanisSwiss LifeOwello

Beyond the preview

Go deeper on DENOS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DENOS.

Explore the full profile